Ventana to Host Symposium Illustrating the Value of Companion Diagnostics on October 4, 2007
Posted on: Wednesday, 3 October 2007, 09:00 CDT
Ventana Medical Systems, Inc. (NASDAQ: VMSI), the global leader in tissue-based cancer diagnostics, today announced that it will host a Companion Diagnostics Symposium on Thursday, October 4, 2007, in New York.
The event will demonstrate the value of companion diagnostics and the promise of personalized medicine from the perspective of pharmaceutical companies, clinicians, diagnostic companies, patients, payors and the FDA. The symposium will include several presentations by companion diagnostic industry experts, including:
Edward Abrahams, PhD, Executive Director, Personalized Medicine Coalition
Richard Hockett, MD, Director of Genomic Medicine, Eli Lilly and Company
Jeffrey Cossman, MD, Chief Science Officer, The Critical Path Institute
Kenneth Bloom, MD, FCAP, Chief Medical Officer and Medical Director, Clarient, Inc.
Eddie Blair, PhD, MBA, Managing Director, Integrated Medicine Ltd
Thomas Grogan, MD, Senior Vice President, Medical Affairs and Founder, Ventana
Paul Beresford, PhD, General Manager of Translational Diagnostics, Ventana
Interested parties may access the live webcast by visiting the Investor section of www.ventanamed.com or by cutting and pasting the following link in their web browser: http://phx.corporate-ir.net/phoenix.zhtml?p= irol-eventDetails&c=79080&eventID=1659373. (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.) An archive of the webcast will be available for one week following the event.
ABOUT VENTANA MEDICAL SYSTEMS, INC.
Ventana develops, manufactures, and markets instrument/reagent systems that automate tissue preparation and slide staining in clinical histology and drug discovery laboratories worldwide. The Company's clinical systems are important tools used in the diagnosis and treatment of cancer and infectious diseases. Ventana's drug discovery systems are used to accelerate the discovery of new drug targets and evaluate the safety of new drug compounds.
For more information on Ventana Medical Systems, Inc. visit www.ventanamed.com.
Source: Business Wire
Related Articles
- Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development
- Power3 Medical Products Advances the Diagnostic Capabilities of the Company's Alzheimer's Disease Biomarkers
- How Overcoming the Challenge of Biomarker Validation Can Pay Off for Drug and Diagnostic Developers
- Kidneys and Genito-Urinary System - Overactive Bladder Drug Pipeline Report Provides Detail on the Top 20 Companies With Products in the Early and Late Stage of Development
- Kidneys and Genito-Urinary System - Urinary Incontinence Drug Pipeline Report - Study the Top 20 Companies in Early and Late Stage of Development
- TeamHealth Announces David Pelini, M.D., As System Medical Director for Memorial Hermann Health System ED Contract
- Research and Markets: Central Nervous System - Alzheimer Disease Drug Pipeline Report
- Cardiovascular and Circulatory System - Myocardial Infarction Drug Pipeline Report
- Key Research on Cancer Stem Cells and Their Relevance and Impact on Drug and Diagnostic Discovery
- Utilization of Indigenous Systems of Medicine & Homoeopathy in India
 |
 |
User Comments (0)
RSS Feeds